Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
CHF 5188 pMDI
Budesonide extrafine pMDI
Seretide(r) Evohaler(r)
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Moderate or severe asthma partly controlled with ICS or ICS/LABA
- FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value
Exclusion Criteria:
- Diagnosis of COPD
- History or current evidence of significant cardiovascular disease
- Uncontrolled concomitant disease
Sites / Locations
- The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
CHF 5188 pMDI
Budesonide extrafine pMDI
Seretide(r) Evohaler(r)
Arm Description
Outcomes
Primary Outcome Measures
Trough FEV1 (mean 23h-24h FEV1)
Secondary Outcome Measures
Trough FEV1 and forced vital capacity (FVC) (mean 23h-24h)
Trough FVC (mean 23-24h)
Peak FEV1 and FVC
FEV1 AUC0-24
Full Information
NCT ID
NCT01070524
First Posted
February 17, 2010
Last Updated
March 28, 2017
Sponsor
Chiesi Farmaceutici S.p.A.
1. Study Identification
Unique Protocol Identification Number
NCT01070524
Brief Title
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Official Title
A Randomised, Double-blind, Active-controlled, 3 Way Cross-over Study to Evaluate the Effect on Trough FEV1 After 4 Weeks Treatment With CHF 5188 pMDI qd (Fixed Combination Budesonide / Carmoterol) in Adult Patients With Moderate or Severe Persistent Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Chiesi Farmaceutici S.p.A.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
Detailed Description
A randomised, double-blind, multinational, multicentre, active-controlled, 3-way cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with moderate or severe persistent asthma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
113 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CHF 5188 pMDI
Arm Type
Experimental
Arm Title
Budesonide extrafine pMDI
Arm Type
Active Comparator
Arm Title
Seretide(r) Evohaler(r)
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
CHF 5188 pMDI
Intervention Description
CHF 5188: fixed combination budesonide/carmoterol
Intervention Type
Drug
Intervention Name(s)
Budesonide extrafine pMDI
Intervention Description
Budesonide extrafine pMDI
Intervention Type
Drug
Intervention Name(s)
Seretide(r) Evohaler(r)
Intervention Description
Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
Primary Outcome Measure Information:
Title
Trough FEV1 (mean 23h-24h FEV1)
Time Frame
after day 28 dose
Secondary Outcome Measure Information:
Title
Trough FEV1 and forced vital capacity (FVC) (mean 23h-24h)
Time Frame
after day 1 dose
Title
Trough FVC (mean 23-24h)
Time Frame
after day 28 dose
Title
Peak FEV1 and FVC
Time Frame
on day 1 and day 28
Title
FEV1 AUC0-24
Time Frame
after day 1 and day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Moderate or severe asthma partly controlled with ICS or ICS/LABA
FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value
Exclusion Criteria:
Diagnosis of COPD
History or current evidence of significant cardiovascular disease
Uncontrolled concomitant disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dave Singh, MD
Organizational Affiliation
The Medicines Evaluation Unit Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom
12. IPD Sharing Statement
Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013759-32
Description
Study Record on EU Clinical Trials Register including results
Learn more about this trial
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
We'll reach out to this number within 24 hrs